Home > Healthcare > Pharmaceuticals > Finished Drug Form > Exocrine Pancreatic Insufficiency Treatment Market

Exocrine Pancreatic Insufficiency Treatment Market Share

Report ID: GMI9379
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Exocrine Pancreatic Insufficiency Treatment Market Share

The exocrine pancreatic insufficiency (EPI) treatment sector is highly consolidated, featuring a blend of major global pharmaceutical companies and smaller to medium-sized firms vying for market share. A crucial aspect of market strategy involves the continuous introduction of innovative enzyme replacement therapies and other treatment modalities utilizing advanced technologies. Prominent industry players wield significant influence in this dynamic landscape, often driving progress through substantial investments in research and development focused on enhancing treatment efficacy and patient adherence. Additionally, strategic alliances, partnerships, and mergers play a vital role in strengthening market positions and expanding their global presence, particularly in response to evolving regulatory frameworks and increasing patient demand for effective EPI solutions.

Exocrine Pancreatic Insufficiency Treatment Market Companies

Some of the eminent market participants operating in the exocrine pancreatic insufficiency treatment industry include:

Abbott Laboratories
AbbVie
Digestive Care
Essential Pharma
Nestle
Nordmark Pharma
Sun Pharmaceutical Industries
Viatris
Vivus
Zentiva Pharma UK

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global exocrine pancreatic insufficiency treatment industry was valued at approximately USD 2.7 billion in 2023 and is estimated to grow at a 5.6% CAGR from 2024 to 2032, driven by increasing awareness and diagnosis rates.

The pancreatic enzyme replacement therapy (PERT) segment dominated the market with a revenue of USD 2.3 billion in 2023 and is expected to grow significantly over the forecast period due to its effectiveness in improving nutrient absorption and alleviating gastrointestinal issues.

North America exocrine pancreatic insufficiency treatment industry accounted for a 56.9% revenue share in 2023 and is projected to reach USD 2.4 billion by 2032, supported by advanced healthcare infrastructure and broad access to PERT.

Key players in the market include Abbott Laboratories, AbbVie, Digestive Care, Essential Pharma, Nestle, Nordmark Pharma, and Sun Pharmaceutical Industries.